PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons

Related Articles
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
CCR5 and HIV Infection
January 2015
HIV/AIDS: Pre-fusion Env Exposed
January 2015
HIV/AIDS: Slide to Enter
January 2015
Updating ModBase
January 2015
Power in Numbers
August 2014
Quorum Sensing: A Groovy New Component
August 2014
Bacterial CDI Toxins
June 2014
Immunity: One Antibody to Rule Them All
June 2014
Virology: A Bat Influenza Hemagglutinin
March 2014
Virology: Making Sensitive Magic
March 2014
Virology: Visualizing Cyanophage Assembly
March 2014
Virology: Zeroing in on HBV Egress
March 2014
March 2014
Cas4 Nuclease and Bacterial Immunity
February 2014
Microbial Pathogenesis: A GNAT from Pseudomonas
February 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Microbiome: The Dynamics of Infection
September 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Infectious Diseases: A Pathogen Ubiquitin Ligase
May 2013
Infectious Diseases: A Shared Syringe
May 2013
Infectious Diseases: Determining the Essential Structome
May 2013
Infectious Diseases: Targeting Meningitis
May 2013
NDM-1 and Antibiotics
May 2013
Bacterial Hemophores
January 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Microbial Pathogenesis: NEAT Iron
January 2013
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
A signal sensing switch
September 2012
Gauging needle structure
July 2012
Anthrax Stealth Siderophores
June 2012
A Pseudomonas L-serine dehydrogenase
May 2012
Pilus Assembly Protein TadZ
April 2012
Making Lipopolysaccharide
January 2012
Superbugs and Antibiotic Resistance
December 2011
A change to resistance
November 2011
An effective and cooperative dimer
November 2011
The Perils of Protein Secretion
November 2011
Bacterial Armor
October 2011
Breaking down the defenses
September 2011
Moving some metal
August 2011
Capsid assembly in motion
April 2011
Know thy enemy … structurally
October 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Hemolysin BL
January 2010
Unusual cell division
October 2009
Anthrax evasion tactics
September 2009
Toxin-antitoxin VapBC-5
September 2009
Antibiotic target
August 2009
July 2009
Tackling influenza
June 2009
You look familiar: the Type VI secretion system
June 2009
Unique SARS
April 2009
Anthrax stealth molecule
March 2009
A new class of bacterial E3 ubiquitination enzymes
January 2009
Antiviral evasion
October 2008
SARS connections
September 2008
SARS Coronavirus Nonstructural Protein 1
June 2008

Research Themes Infectious diseases

Superbugs and Antibiotic Resistance

SBKB [doi:10.3942/psi_sgkb/fm_2011_12]
Featured System - December 2011
Short description: Antibiotics were used as weapons to fight bacteria long before Alexander Fleming discovered penicillin.

Antibiotics were used as weapons to fight bacteria long before Alexander Fleming discovered penicillin. Natural antibiotics like penicillin are made by fungi and other organisms to protect themselves, and as you might expect, bacteria have found many ways to avoid these protections. For instance, beta-lactamases, enzymes that break a key bond in penicillin, were discovered in antibiotic-resistant bacteria before penicillin was ever used in the clinic. However, our widespread use of antibiotics has escalated the battle, leading to the rise of "superbugs" that are resistant to most of the currently known antibiotics. The bacteria have a great advantage in this battle: they grow quickly, they are found in huge numbers, and they have many efficient methods to exchange genes with other resistant bacteria.


NDM-1 (New Delhi metallo-beta-lactamase, shown here from PDB entry 3sfp), is a recent development in this battle. It is an enzyme that destroys almost all known beta-lactam antibiotics, including familiar antibiotics like penicillin as well as specialized carbapenem antibiotics that were specifically designed to fight resistance. To make things worse, the gene for this enzyme is readily traded between bacteria in a plasmid that includes other anti-antibiotic weapons, including enzymes that break down other types of antibiotics like erythromycin and chloramphenicol and a special pump that ejects antibiotics out of bacterial cells.

Destroying Drugs

As with many other enzymes involved in antibiotic resistance, NDM-1 modifies antibiotics, rendering them ineffective. Some of these enzymes, such as APH(4)-Ia (shown here from PDB entry 3tyk) attach bulky groups like phosphates or nucleotides to the drug, making them too big to bind to their bacterial targets. Others, like NDM-1, break bonds in the antibiotic, destroying its ability to form a covalent bond to the target. NDM-1 uses two zinc ions in its cleavage reaction, that activate a water molecule and stabilize an intermediate form of the antibiotic, making sure that the reaction proceeds smoothly. NDM-1 is also surprisingly effective against many different antibiotics. Structures of NDM-1 from the PSI give an explanation: the active site is much larger than the active sites of similar enzymes. Also, by solving many structures in slightly different states, they have observed that the enzyme is quite flexible, which may be important for accommodating targets of different sizes and shapes.

A Continuing Battle

Of course, researchers are fighting back and devising new ways to block bacterial resistance. Because of its critical importance in this battle, NDM-1 was chosen as a target by the PSI Biology Partnership MBTI and the structure was solved by their high-throughput partner MCSG. As with all PSI structures, the atomic coordinates are released quickly, providing the information needed to design new compounds to block its action. This would allow a two-pronged treatment that would include a traditional beta-lactam antibiotic to block cell wall synthesis and ultimately kill the bacteria, along with a second drug to thwart NDM-1 and protect the antibiotic. The structure of NDM-1 reveals the details of the active site, including the location of the catalytic zinc ions and a flexible loop that may be involved in the ability of the enzyme to attach a wide variety of drugs. To take a closer look at these structures, the JSmol tab below displays an interactive JSmol.

Bacterial E3 Ubiquitin Ligases

Structures of the two domains of bacterial E3 ubiquitin ligases are included in this Jmol: the protein-targetting domain of Salmonella SlrP, and the catalytic domain of Shigella IpaH. Use the buttons to look at the two structures and to change the representation. A key cysteine amino acid is thought to be essential for the ubiquitin-transfer reaction--it is shown in bright yellow spheres in the catalytic domain structure.


  1. Kim, Y. et al. Structure of apo- and monometalated forms of NDM-1 - a highly potent carbapenem-hydrolyzing metallo-beta-lactamase. PLoS One 6, e24621 (2011).

  2. Stogios, P. J. et al. Structure and function of APH(4)-Ia, a hygromycin B resistance enzyme. J. Biol. Chem. 286, 1966-1975 (2011).

  3. Moellering, R. C. NDM-1 - a cause for worldwide concern. New Engl. J. Med. 363, 2377-2379 (2010).

  4. Singer, A. U. et al. Structure of the Shigella T3SS effector IpaH defines a new class of E3 ubiquitin ligases. Nature Struct. Mol. Biol. 15, 1293-1301 (2008).

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health